Gilead: Will Immunomedics Be Gilead’s Next Pharmasset?
Gilead Sciences announced on 13th September that it has entered into a definitive agreement to acquire Immunomedics for US$88.00 per share in cash,...
530 Views
Everest Medicines IPO Initiation: Potent Medicine
Everest Medicines Everest Medicines (EVEREST HK)Â is a biopharmaceutical company which targets four therapeutic areas - oncology, immunology,...
556 Views
Legend Biotech IPO: Pass on Valuation
Legend Biotech (LEGN US)Â is one of the leading companies in developing CAR-T cell therapies in China, having received clearance for the first CAR-T...
624 Views
Gilead to Acquire a Stake in Arcus Biosciences; Offer May Come at a Large Premium
On 16th April 2020, Bloomberg reported that Gilead Sciences is considering acquiring a significant stake in Arcus Biosciences, a cancer...
531 Views
SELL Ascletis Pharma: Why the COVID-19 Update Does Not Make Sense
We have previously discussed the short idea of Ascletis Pharma. After a few days of retreat, the stock reacted positively today to the news related...
501 Views